Latest News and Press Releases

GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 30, 2024 LA JOLLA, CA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the...

Clinical development plan potentially leveraging 505(b)(2) regulatory pathway Currently available treatments for IPF are limited to only two approved drugs that come with significant...

Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on track to start before year end Currently available treatments for IPF are limited to...

Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (“IPF”) on track to start before year end 2023; Interim data expected H1 2024 Currently available treatments for IPF are...

Data presented at the 7th Annual Antifibrotic Drug Development (AFDD) Summit Company’s lead program, GRI-0621, has demonstrated ability to inhibit the activity of type I invariant NKT (iNKT) cells...

Findings demonstrate that the number of NKT cells positively correlates with the number of airway macrophages in IPF patients GRI Bio on track to launch Phase 2a biomarker...

UK consortia brings together internationally recognized investigators in the UK's leading centers of excellence to carry out experimental and early phase research Translational work to be...

- Live moderated webcast with Marc Hertz, Chief Executive Officer of GRI Bio on Tuesday, October 24th at 11:00 AM ET LA JOLLA, CA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:...

In several murine models of chronic inflammation and fibrosis, as well as in humans, it has been shown that iNKT cells are selectively activated in the disease setting Data supports GRI Bio’s...

LA JOLLA, CA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...